Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Hep C Discussion Forum -> General Discussion -> Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress
Post Info TOPIC: Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress
Cinnamon Girl


Guru

Status: Offline
Posts: 5629
Date:
Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress
Permalink  
 

Hi guys, I was reading an article about that.  It should prove a very beneficial arrangement for Achillon, and if it helps gets the drugs to market sooner then many more Hep C sufferers will be benefit too. 

Here`s the link...

http://hcvadvocate.blogspot.ca/2015/05/achillion-enters-into-worldwide.html



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 
Matt Chris


Guru

Status: Offline
Posts: 1782
Date:
Permalink  
 

Hey Bubble

Your correct, in a couple of years when these two company's finish their clinical trials for their HCV combo killer their will still be millions of people world wide needing a better cure for the malady. But Gilead has quite a lead in this race so it will not be easy to catch up, thats why Achillion make a wise move in partnering with a larger Biotech company that can fund the much needed larger clinical trials.

matt 



__________________

"And in the end, the love you take is equal to the love you make"

61 year old Geno type A1, F4 Cirrhotic, started 24 weeks on Harvoni 12-17-14 ,EOT-5 week = UND, 8-31-15 =UND , SVR-24 Baby YES! 
bubble


Senior Member

Status: Offline
Posts: 236
Date:
Permalink  
 

It look's like J+J bought Achillion's Hep C anti viral drug for 1.1B.  This sounds reminisent of when Pharmasset sold to Gilead their work and then teamed up with Bristol-Myers to make the cure known as Harvoni.  Looks like J+J could squash Gilead in the future. I hope this speeds up things for all. The Phama industry is so cut throat. I know they are trying for a 4 week cure. Right now I am reading 100% cure for a group of 18 people. Follow the money, Pray for all.



__________________

60 yrs. Geno1b 2001. 9mil. VL. �Failed Post Riba/Peg tx. 2006 46 weeks. Diagnosed 1A 2015(?) F3 fibr. 225k VL. Vikera/Riba 12 weeks 3/20/2015. "Undetected" start to finish. Undetected 1yr post tx.
angelseven


Senior Member

Status: Offline
Posts: 230
Date:
Permalink  
 

Thanks you guys!!!!



__________________

62 year old female      1a, f1-2, had virus 40 years   STARTED HARVONI for 8 weeks 11/19/14, relapsed one month after tx  ended in 1/15.  Fibrosis level was only .5 after fibroscan 12/15. Began treatment with Mavyret on January 20, 2018 for 16 weeks!  Ending May 12.
mallani


Guru

Status: Offline
Posts: 3398
Date:
Permalink  
 

Hi Connie,

Matt has given some good links.

Achillion Pharmaceuticals may have good alternatives. Their antiprotease, ACH-1625 (now called Sovaprevir) has breakthrough status, and is pan-genotype. It is similar to MK-5172.

Their NS-5A inhibitor, ACH-3102, is second generation and is claimed to be effective against the RAV's that arise after Ledipasvir and Daclatasvir treatment failures. It is currently in Phase 2 Trials, and has achieved great results with only 6 and 8 weeks of combination treatment with Sovaldi. The patients were all Rx-naive and the numbers are small (18).

Achillion are also trialling their Sovaldi alternative, ACH-3422. This is claimed to be a very potent nucleoside NS-5B blocker.

It's too early to give an opinion of their drugs, but they will be an obvious choice for Harvoni failures if the great results continue.

We are now getting more data about the RAV's at NS-5A- they are obviously going to be a problem for some patients.

I'll give you a proper reply in 6-9 months. Cheers.



__________________

Geno 1b, IL28B CT,  x3 prior relapser,  ex-cirrhotic, 75 yo, did 48 weeks with Victrelis/Peg./Riba.  VL 1.28m at start, UNDET. at 8 ,12 ,16 ,24 ,30  and 48 weeks.  EOT 15 Feb 2013 , UNDET. at EOT + 28 weeks. SVR!  Still Undet. at EOT +5 years

Malcolm
angelseven


Senior Member

Status: Offline
Posts: 230
Date:
Permalink  
 

Hey Matt,  I talked to my hepalogist office (Dr Galati) about this testing... they are really clueless, I showed them several of the tests that Quest does to check for sofosbuvir and ledipasvir resistance... they were not interested in this at all... I think I might have to switch back over to Baylor ... they have more research going on and you actually can see a real doctor... but it is kind of like a zoo there and hard to get anyone on the phone...
I guess there is the deep DNA testing, is this what you are referring to... no sense doing anything right til I know what the new meds are... I am not jumping into treatment in the first year the meds are released this time... as long as my fibrosis is low and I can wait...
This is complicated stuff and I am not nearly educated enough to comprehend it all!!!
Thanks, I am going to get my friend on here... she also relapsed following 12 weeks of harvoni... she was treatment naïve but higher viral load... maybe 6,000 ,,,.. she went through the same pattern I did... undetected until 4 weeks following EOT
Honestly, at first I thought maybe I did not do the harvoni long enough, but my gut feeling now is that I am resistant to it...
I think it will get to a point where they can test your blood and figure out the exact treatment for you with 100% accuracy... what ya think??
Hope you are doing well!! 
Connie/angelseven
Matt Chris wrote:

Hey Connie

Thanks for the link, it good to see that your staying on top of the HCV treatment developments. I read about this also from the EASL conference, though it was a very small study number the results are very promising. As time passes and we see more real world data on Harvoni patients. In the coming months doctors and HCV treatments specialists will have to address the best way to handle relapsed patients.

There was a study released at the EASL ( Dr. Lawitz) on re-treatment on patients that failed Gilead's trials on Sofosbuvie & Ledipasvir (Harvoni) that had some interesting points, here is the link

http://www.natap.org/2015/EASL/EASL_26.htm   and also

ttp://www.healio.com/hepatology/hepatitis-c/news/online/%7Bb067e467-93a0-4853-83ce-ab4b82d67aef%7D/ns5a-ravs-may-persist-through-96-weeks-after-ledipasvir-therapy#

Connie I think I mentioned this before. but in case I have not, If I were you I would want to know if the cause of my relapse was by RAV's and if so what location so you know what future choices of treatment maybe your best option.  It maybe that you did't develop any RAV's during the eight weeks and that it just was not a long enough treatment duration.

I my own 12 week DAA treatment relapse its showed via population sequencing no present RAV's.  I know its a expense test but these types of lab tests will be more common in the coming years and with your good health status you may able to wait a year or so.

I know how you feel so hang in there your future has not been written yet.

matt           

 



__________________

62 year old female      1a, f1-2, had virus 40 years   STARTED HARVONI for 8 weeks 11/19/14, relapsed one month after tx  ended in 1/15.  Fibrosis level was only .5 after fibroscan 12/15. Began treatment with Mavyret on January 20, 2018 for 16 weeks!  Ending May 12.
Matt Chris


Guru

Status: Offline
Posts: 1782
Date:
Permalink  
 

Hey Connie

Thanks for the link, it good to see that your staying on top of the HCV treatment developments. I read about this also from the EASL conference, though it was a very small study number the results are very promising. As time passes and we see more real world data on Harvoni patients. In the coming months doctors and HCV treatments specialists will have to address the best way to handle relapsed patients.

There was a study released at the EASL ( Dr. Lawitz) on re-treatment on patients that failed Gilead's trials on Sofosbuvie & Ledipasvir (Harvoni) that had some interesting points, here is the link

http://www.natap.org/2015/EASL/EASL_26.htm   and also

http://www.healio.com/hepatology/hepatitis-c/news/online/%7Bb067e467-93a0-4853-83ce-

ab4b82d67aef%7D/ns5a-ravs-may-persist-through-96-weeks-after-ledipasvir-therapy#

Connie I think I mentioned this before. but in case I have not, If I were you I would want to know if the cause of my relapse was by RAV's and if so what location so you know what future choices of treatment maybe your best option.  It maybe that you did't develop any RAV's during the eight weeks and that it just was not a long enough treatment duration.

I my own 12 week DAA treatment relapse its showed via population sequencing no present RAV's.  I know its a expense test but these types of lab tests will be more common in the coming years and with your good health status you may able to wait a year or so.

I know how you feel so hang in there your future has not been written yet.

matt           



__________________

"And in the end, the love you take is equal to the love you make"

61 year old Geno type A1, F4 Cirrhotic, started 24 weeks on Harvoni 12-17-14 ,EOT-5 week = UND, 8-31-15 =UND , SVR-24 Baby YES! 
angelseven


Senior Member

Status: Offline
Posts: 230
Date:
Permalink  
 

OK, since I relapsed with Harvoni, I am trying to see what is the next best treatment down the road... this appears to be for relapsers

Malani, if you are out there I am wondering what you think about it??

http://money.cnn.com/news/newsfeeds/articles/globenewswire/10130749.htm

 

Thanks, Connie/angelseven

 



__________________

62 year old female      1a, f1-2, had virus 40 years   STARTED HARVONI for 8 weeks 11/19/14, relapsed one month after tx  ended in 1/15.  Fibrosis level was only .5 after fibroscan 12/15. Began treatment with Mavyret on January 20, 2018 for 16 weeks!  Ending May 12.
Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.
Hep C Discussion Forum -> General Discussion -> Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress
Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.